Double success for Chandler Robinson

  • February 4, 2020
Double success for Chandler Robinson

Chandler Robinson's second company has recently been described as having the best first day for an IPO since the tech giant Baidu.

The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.

Chandler Robinson

A business venture started by Gates Cambridge Scholar Chandler Robinson recently IPO’d and experienced the “best first-day pop for an IPO since [Chinese tech company] Baidu in 2005”, according to Nasdaq News.

After the initial public offering through which private companies seek to raise capital from public investors, the company’s stock price jumped 231 percent on its first day, reaching a market valuation of $289 million.

The company, Monopar Therapeutics Inc. (Nasdaq: MNPR), is Chandler’s second successful biotech exit since completing his studies at the University of Cambridge in 2010. The first company Chandler co-founded was Tactic Pharma. It was started immediately following his completion of the MBA at Cambridge. Tactic Pharma’s lead drug was a compound which Chandler had researched in depth as an undergraduate and published on in Science. He was the CEO of Tactic and its lead drug went on to have promising phase 2 clinical data in Wilson Disease patients and was acquired by Alexion for $855M.

Chandler’s current company, Monopar, where he is again the CEO, is focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. The company's pipeline consists of Validive® for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, Camsirubicin for the treatment of advanced soft tissue sarcoma, and a late-stage preclinical antibody MNPR-101 for the treatment of several solid tumours.

Chandler gives a lot of credit to the Gates Cambridge Scholarship and the Bill and Melinda Gates Foundation, which he said “enabled me to pursue an MBA when I otherwise wouldn’t have been able to afford it. The Cambridge MBA gave me an opportunity to hone my leadership and business judgment skills, which in turn gave me the confidence and ability to manage and operate these companies.”

Latest News

Why a one-size-fits-all approach to biodiversity won’t work

Carmen Lacambra Segura is keen to tackle the challenges affecting biodiversity from an interdisciplinary perspective which takes into account all the different factors that affect it. That means taking more contextualised approaches and using data to make positive progress. She has worked for over 30 years on resilience and climate adaptation, integrating science and evidence-based […]

Exploring the emotions behind Archaeology

Archaeology is a discipline that excavates the past, piecing together scant and often disparate details to answer questions about how people lived, grew, interacted and died. For Madalyn Grant [2024], this means that Archaeology is a discipline steeped in human emotions. Yet, for a subject so infused with emotion, its practitioners tend not to confront […]

Making waste work

Luca Di Mario’s PhD in Engineering focused on sustainable business models for turning solid waste and waste water in developing countries into a useful resource, such as energy.   That work has stood him in good stead for his work at the Asian Development Bank where he is currently Senior Advisor to the Vice President for […]

A changing man

The world has always been in flux, but the last decades, particularly the recent one, have been ones of rapid, often violent, transformation on many fronts. For Jaya Savige [2008] the last 11 years since leaving Cambridge have been characterised by profound change on both the personal and professional front. He has captured all of that […]